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The hemagglutinin-esterase (HE) membrane glycoprotein is present only in some members of the coronavirus family, 
including some strains of mouse hepatitis virus (MHV). In the JHM strain of MHV, expression of the HE gene is variable 
and corresponds to the number of copies of a UCUAA pentanucleotide sequence present at the 3’-end of the leader 
RNA. This copy number varies among MHV strains, depending on their passage history. The JHM isolates with two 
copies of UCUAA in their leader RNA showed a high level of HE expression, whereas the JHM isolate with three copies 
had a low-level expression. In this study, the analysis of HE gene expression was extended to other MHV strains. The 
synthesis of HE mRNA in these viruses also correlates with the copy number of UCUAA in the leader RNA and the 
particular intergenic sequence preceding the HE gene. In one MHV strain, MHV-1, no detectable HE mRNA was 
synthesized, despite the presence of a proper transcription initiation signal. This lack of HE mRNA expression was 
consistent with a leader RNA containing three UCUAA copies. However, mutations and deletions within the coding 
region of the MHV-1 HE gene have generated a stretch of sequence which resembled the transcriptional initiation 
motif, and was shown to initiate the synthesis of a novel smaller mRNA. These findings strengthened the theory that 
interactions between leader RNA and transcriptional initiation sequences regulate MHV subgenomic mRNA transcrip- 
tion. Sequence analysis revealed that most MHV strains, through extensive mutations, deletions, or insertions, have 
lost the complete HE open reading frame, thus turning HE into a pseudogene. This high degree of variation is unusual 
as the other three structural proteins (spike, membrane, and nucleocapsid) are well-maintained. In contrast to bovine 
coronavirus, which apparently requires HE for viral replication, the HE protein in MHV may be only an accessory pro- 
tein which is not necessary for viral replication. JHM and MHV-S, however, have preserved the expression of HE 
protein. 0 1991 Academic Press, Inc. 
INTRODUCTION 
Coronavirus virions are enveloped particles contain- 
ing three or four structural proteins: spike (S) protein, 
membrane (M) protein, nucleocapsid (N) protein, and 
hemagglutinin-esterase (HE) protein (Lai, 1990). The S 
protein is a glycoprotein of 180 kDa, which often is 
cleaved by host proteases into two 90-kDa subunits 
(Yoshikura and Tejima, 1981; Sturman et a/., 1985). 
This protein, which is the outermost protein on the viral 
envelope, interacts with the host cell receptor, causes 
cell-cell fusion, and elicits neutralizing antibodies (Col- 
lins et a/., 1982; Sturman and Holmes, 1983; Sturman 
et al., 1985). The M protein is a transmembrane glyco- 
protein of 23 kDa, which appears to interact with the 
nucleocapsid inside the virus particle (Sturman et a/., 
1980). The N protein is a phosphoprotein of 50-60 kDa 
in size, which interacts with viral RNA (Stohlman et al., 
1988). The HE protein is an additional glycoprotein of 
Sequence data from this article have been deposited with the 
EMBUGenBank Data Libraries under Accession Nos. M64313, 
M64314. M64315, and M64316. 
’ To whom reprint requests should be addressed. 
65 kDa, which projects from the viral envelope (King et 
a/., 1985; Yokomori eta/., 1989). While the S, M, and N 
are present in all coronaviruses, the HE protein is de- 
tected only in some species of coronavirus, such as 
bovine coronavirus (BCV) (King et al., 1985; Vlasak et 
a/., 1988a; Parker et al., 1989) turkey coronavirus 
(TCV) (Dea and Tijssen, 1988), and human coronavirus 
(OC43) (Hogue et al., 1984; Hogue and Brian, 1986) 
but not in avian infectious bronchitis virus (IBV) or por- 
cine transmissible gastroenteritis virus (TGEV) (Garwes 
and Reynolds, 1981; Stern and Sefton, 1982). 
Mouse hepatitis virus (MHV) is the prototypic 
member of the Coronaviridae, which contains a non- 
segmented, positive-sensed genomic RNA of 3 1 kb in 
length (Pachuk et a/., 1989; Lee et a/., 1991). In in- 
fected cells, seven or eight virus-specific mRNA spe- 
cies are detected. The mRNAs are characterized by a 
nested-set structure with common 3’-terminal se- 
quences but with unique 5’-regions (Lai et a/., 1981; 
Leibowitz et al,, 1981). Although structurally polycis- 
tronic, each mRNA encodes only one protein, which is 
translated from the unique 5’-region. For instance, the 
S protein is translated from mRNA 3, M protein from 
mRNA 6, and N protein from mRNA 7 (Leibowitz et a/., 
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1982; Siddell, 1983). In addition, the mRNAs possess a 
common leader sequence of approximately 72 nucleo- 
tides in length, which is derived from the 5’-end of the 
viral genome (Spaan et al., 1983; Lai et al., 1984). The 
3’-end of the leader RNA contains a pentanucleotide 
sequence of UCUAA, which is homologous to the in- 
tergenic sequences present at the beginning of each 
gene. The copy number of this pentanucleotide se- 
quence was two to four, depending on the particular 
virus strain (Makino eta/., 1988) and varied after serial 
passage of virus in cell culture (Makino and Lai, 
1989a). For example, in the neurotropic JHM strain of 
MHV, the wild-type virus contained three copies of 
UCUAA; but after 10 to 12 passages, the number of 
copies was reduced to two (Makino and Lai, 1989a). 
This change was accompanied by an alteration in the 
pattern of mRNA expression (Makino and Lai, 1989a). 
Specifically, the JHM variant with two copies of UCUAA 
(designated as JHM(2)) made a large amount of mRNA 
2-1, while wild-type JHM with three copies (JHM(3)) 
made only a small amount (Makino and Lai, 1989a; 
Shieh et a/., 1989). In vitro translation studies revealed 
that HE protein was encoded by mRNA 2-l (Shieh ef 
a/., 1989). Thus, HE protein expression in JHM was 
controlled by the copy number of UCUAA in the leader 
(Makino and Lai, 1989a; Shieh et al., 1989). 
The HE protein possesses an esterase activity simi- 
lar to the receptor-destroying enzyme (RDE) of influ- 
enza C virus (Vlasak et al., 1988b), and also a hemag- 
glutinin activity (Vlasak et a/., 1988b; Parker et a/., 
1989). However, the hemagglutinin activity in JHM is 
very weak (Yokomori et a/., 1989). In order to better 
understand the biological significance of the HE pro- 
tein, we examined the structure and expression of HE 
in several different strains of MHV. The results demon- 
strated that HE expression varied at both transcrip- 
tional and translational levels amongst MHV strains. In 
contrast to the conserved expression of the other three 
structural proteins, S, M, and N, the HE gene in most 
MHV strains appears to be a pseudogene. The signifi- 
cance of the maintenance of HE expression in some of 
the MHV strains will be discussed. 
MATERIALS AND METHODS 
Viruses and cell culture 
The MHV strains used in this study were from sev- 
eral different sources. Plaque-cloned JHM(2) and 
JHM(3) viruses (Makino and Lai, 1989a; Shieh et al., 
1989; Yokomori et a/., 1989) which have two and three 
copies of UCUAA in the leader sequence, respectively, 
and strain A59 were the same as those reported in a 
previous study (Yokomori et al., 1989). The two vari- 
ants of JHM-DL (a large-plaque variant of JHM (Weiner, 
1973; Stohlman et a/., 1982)) containing two or three 
copies of UCUAA were obtained by a modification of 
the published procedures (Makino and Lai, 1989a). 
Briefly, JHM-DL was passaged serially without dilution 
in DBT cells, a murine astrocytoma cell line (Hirano et 
al., 1974). Virus harvested at the end of the fifth pas- 
sage was passaged one additional time in DBT cells at 
low multiplicity of infection (m.o.i.) to eliminate possible 
DI particles. Virus variants were plaque-purified, and 
the number of UCUAA copies at the 3’-end of the 
leader was determined by primer extension (Makino et 
al., 1988). Viruses with either two or three copies of 
UCUAA in the leader were designated JHM-DL(2) and 
JHM-DL(3), respectively. MHV-1 and MHV-S were ob- 
tained from Dr. Paul Masters of Wadsworth Center for 
Laboratories and Research, New York State Depar-t- 
ment of Health. MHV-2 has been described previously 
(Lai and Stohlman, 1981). Two isolates of MHV-3, i.e., 
MHV-3-L and MHV-3-Yac, were plaque-purified from 
stocks originally obtained from Dr. Lucie Lamontagne 
of the University of Montreal. Viruses were propagated 
in DBT cells as described previously (Makino et a/,, 
1984b). DBT cells also were used for all the in vivo 
metabolic labeling experiments. 
35S-labeling of intracellular proteins and preparation 
of cell lysates 
Intracellular proteins of virus-infected DBT cells were 
labeled, and cell lysates made as described previously 
(Yokomori et a/., 1989). Briefly, when the cytopathic 
effect (CPE) in MHV-infected DBT cells reached 95%, 
cells were starved in methionine-free media for 30 min, 
and then [35S]methionine (1 193 Ci/mmol; ICN Transla- 
bel) was added to a final concentration of 50 &i/ml. 
Cells were pulse-labeled for 20 min and then immedi- 
ately placed on ice, washed with ice-cold phosphate- 
buffered saline (PBS), and lysed with lysis buffer (1% 
Triton X-100, 0.5% sodium deoxycholate, and 0.1% 
SDS in PBS) containing 1 mM phenylmethylsulfonyl flu- 
oride (PMSF; Sigma). Cell lysates were passed through 
a 19-gauge syringe needle five times, transferred to 
Eppendorf tubes, and spun at 12,OOOgfor 10 min at 4”. 
Supernatant were harvested and stored at -70” until 
required. 
lmmunoprecipitation and SDS-PAGE 
lmmunoprecipitation was performed as previously 
described (Yokomori eta/., 1989) using rabbit hyperim- 
mune serum prepared against purified JHM(2) virus 
(Yokomori et a/., 1989). After immunoprecipitation, 
samples were denatured in 2X sample buffer (0.06 M 
Tris-HCI, 2% SDS, 25% glycerol, 5% 2-mercaptoeth- 
anal, and 0.1% bromphenol blue) at 37” for 20 to 30 
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min, and centrifuged at 12,000g for 5 min. The super- 
natants were electrophoresed on 7.5 to 15% gradient 
or 12.5% straight polyacrylamide gels containing 
0.1% SDS. 
32P-labeling of intracellular RNA of virus-infected 
cells 
DBT cells were infected with various strains of MHV 
at an m.o.i. of 1-5. Virus-infected cells were labeled 
with 200 &i/ml of [32P]or-thophosphate (ICN Biochemi- 
cals) from 5.5 to 8 hr postinfection in the presence of 
actinomycin D (2.5 pglml, Sigma). RNA extraction was 
performed as described below. 
Preparation of virion RNA and intracellular RNA 
Virion RNA was purified by a modification of the pro- 
cedure described by Makino et al. (1984a). DBT cells 
were infected at an m.o.i. of 1-5. Culture supernatant 
was harvested at 15-20 hr postinfection, and cell de- 
bris removed by centrifugation at 1500 rpm for 5 min. 
Virus was then precipitated by the addition of ammo- 
nium sulfate to 50% saturation, and purified by ultra- 
centrifugation twice in discontinuous sucrose gra- 
dients (Banner er a/., 1990). The virus pellet was incu- 
bated at 37” for 1 hr in a solution containing 100 pg/ml 
of proteinase K, 100 mM Tris-HCI (pH 7.5), 12.5 mM 
EDTA, 150 mM NaCI, and 1% SDS, extracted twice 
with phenol/chloroform (l/l) and the RNA precipitated 
with ethanol. Virion RNA isolated was used for RNA 
sequencing and primer extension. Intracellular RNA 
was isolated essentially as described by Makino et a/. 
(1984b). Briefly, infected cells were lysed at 9 hr postin- 
fection with NTE buffer (0.1 M NaCI, 0.01 M Tris-HCI, 
pH 7.2, and 1 mM EDTA) containing 0.5% Nonidet 
P-40, and the nuclei were removed by brief centrifuga- 
tion. Supernatants were treated with proteinase K and 
the RNA extracted as described above for virion RNA. 
cDNA cloning of viral mRNAs by polymerase chain 
reaction (PCR) 
cDNA clones corresponding to the 5’-unique cod- 
ing region of mRNA 2-1 were produced using PCR 
as described previously (Makino et al,, 1988). Intra- 
cellular RNA from virus-infected cells was annealed 
with primer 226 (5’-CTAACACCGCTATCCGTCAT-3’) 
which is complementary to the 3’-conserved region 
of gene 2-1, and cDNA was synthesized with re- 
verse transcriptase (Boehringer Mannheim Biochemi- 
cals). For PCR amplification of the cDNA, a second 
primer, 78 (5’-AGCTTTACGTACCCTCTCTACTCTAA- 
AACTCTTGTAGTTT-3’) which is homologous to the 
5’-end of the leader plus 7 additional nucleotides con- 
taining the SnaBl restriction site, was added (Makino 
and Lai, 1989b). The mixture was incubated for 25 cy- 
cles of 94” for 30 set, 54” for 90 set, and 72” for 3 
min. PCR products representing the 5’-region of mRNA 
2 (2.1 kb, consisting of 0.8 kb from gene 2 and 1.3 kb 
from HE gene) and 2-l (1.3 kb) were excised from low 
melting agarose (Sea Plaque, FMC Bioproducts, Rock- 
land, ME) and extracted with phenol and chloroform. 
The cDNA was phosphorylated and blunt-ended with 
polynucleotide kinase and T4 DNA polymerase 
(Boehringer Mannheim Biochemical@, and ligated into 
the Smal site of the vector pTZ18U (United States Bio- 
chemical Corp). 
RNA and DNA sequencing 
RNA sequencing of purified virion genomic RNA was 
performed using modification of the dideoxyribonu- 
cleotide chain-termination method @anger eta/., 1977) 
as described previously (Banner eta/., 1990). Primer 56 
(5’-CGCCGAATGGACACGTC-3’), which iscomplemen- 
tary to nucleotides 172 to 188 from the 5’-end of geno- 
mic RNA (Makino and Lai, 198913) was used to obtain 
the sequence of the leader RNA, including the UCUAA 
repeat region. For the HE gene sequence, DNA se- 
quencing was carried out by dideoxyribonucleotide 
chain-termination method (Sanger et al., 1977), using 
primers corresponding to different regions of the gene. 
Some regions also were confirmed by RNA sequenc- 
ing with the same primers and the method described 
above. 
ln vitro transcription and translation 
Recombinant plasmid pTZl8U(HE), derived from 
PCR products of various strains of MHV, were con- 
structed such that the T7 RNA polymerase promoter 
preceded the leader sequence and translation initia- 
tion site of the HE gene. Plasmids were linearized by 
digestion with &al and transcribed in vitro with T7 
RNA polymerase as described previously (Makino and 
Lai, 1989b). The RNA transcripts were translated in a 
mRNA-dependent rabbit reticulocyte lysate or wheat 
germ extract (Promega Biotec) in the presence of 
[35S]methionine (NEN Du Pont), with or without canine 
pancreatic microsomal membrane (Promega Biotec). 
Reactions were carried out as recommended by the 
manufacturer. 
RESULTS 
Detection of intracellular virus-specific HE protein 
from various strains of MHV 
To examine the HE expression of different MHV 
strains, virus-infected cells were labeled with [35S]me- 
thionine, and the virus-specific proteins were im- 
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FIG. 1. SDS-PAGE analysis of intracellularviral proteins of different 
MHV strains. Virus-infected cells were radiolabeled with [35S]methi- 
onine for 20 min at 8 to 10 hr postinfection. Cell lysates were immu- 
noprecipitated with anti-JHM(2) rabbit serum (Yokomori er al., 1989), 
and analyzed by electrophoresis on 7.5 to 15% gradient polyacryl- 
amide gels. The arrows indicate viral structural proteins. Lanes S, 1, 
2, and 3 represent MHV-S, MHV-1, MHV-2, and MHV-3, respec- 
tively. 
munoprecipitated with polyclonal antibodies directed 
against JHM(2) virions. Figure 1 shows that while large 
amounts of HE protein could be detected in cells in- 
fected with MHV-S, JHM(2), and JHM-DL(2), only small 
amounts were detected in JHM(3)- and JHM-DL(3)-in- 
fected cells. This finding is consistent with our 
previous studies, which showed that JHM viruses with 
three copies of UCUAA in the leader RNA synthesized 
a much lower amount of HE protein than the virus with 
two UCUAA copies (Shieh et al., 1989; Yokomori eta/., 
1989). Since the JHM and JHM-DL variants with differ- 
ent copy numbers of UCUAA were isolated indepen- 
dently from different virus stocks, these findings further 
suggest that variations in the amount of HE protein are 
related to the copy number of UCUAA rather than 
some other mutation(s). Strains A59, MHV-1, MHV-2, 
and two different plaque isolates of MHV-3 did not syn- 
thesize HE or any other additional proteins which could 
be recognized by anti-JHM(2) polyclonal antibodies. 
These results showed that many strains of MHV do not 
express HE protein. In contrast to HE, the other three 
structural proteins (S, N, and M) were synthesized con- 
sistently by all viruses. 
mRNA 2-1 expression by different strains of MHV 
To determine whether the lack of synthesis of HE 
protein by different MHV strains was at the transcrip- 
tional or translational level, 3’P-labeled virus-specific 
mRNA from virus-infected cells was examined by aga- 
rose gel electrophoresis after glyoxal denaturation. Fig- 
ure 2 shows the intracellular mRNA patterns of the 
various strains of MHV. Surprisingly, mRNA 2-1, which 
encodes HE protein, was synthesized by most of the 
viruses, including MHV-2, and two isolates of MHV-3, 
even though these strains failed to synthesize any HE- 
related protein (Fig. 1). Thus, the mRNA 2-l of MHV-2 
and MHV-3 was nonfunctional, or defective in transla- 
tional control. Consistent with their failure to express 
HE protein, mRNA 2-l was not detected in A59 or 
M HV- 1 -infected cells. 
Previously we have shown that JHM(3) synthesizes 
less mRNA 2-1 than JHM(2) (Makino and Lai, 1989a, 
Shieh et a/., 1989). In this study, we confirmed this 
observation (Fig. 2) and extended it to include the large 
plaque variant of JHM, JHM-DL. Specifically, substan- 
tially more mRNA 2-l was detected in cells infected 
with JHM-DL(2), which contains two copies of UCUAA, 
than JHM-DL(3), which contains three copies of 
UCUAA (Fig. 2). The amounts of HE protein synthe- 
sized by these viruses (Fig. 1) correlated well with the 
amounts of mRNA 2-l synthesized. 
Figure 2 also revealed that MHV-1, which failed to 
synthesize any detectable mRNA 2-1, synthesized a 
novel mRNA species, which was smaller than mRNA 
‘; 
-6 
-7 
FIG. 2. Intracellular viral RNA of different MHV strains. Intracellular 
RNA of virus-infected cells was labeled with [32P]orthophosphate for 
2 hr and isolated when cytopathic effect (CPE) reached 85 to 95%. 
RNA was denatured with glyoxal and analyzed by electrophoresis on 
a 1% agarose gel. Although all viral RNAs were analyzed on one gel 
at the same time, different lanes from the same gel were exposed for 
various times to adjust the intensity of the bands. Lane designations 
are the same as in Fig. 1. Virus-specific mRNA species are indicated 
by numbers, and mRNA 2-l IS indicated by small arrowheads. The 
novel mRNA between mRNA 2 and mRNA 3 in MHV-1 is indicated by 
the larger arrowhead. 
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2-l but larger than mRNA 3. Since no HE-related pro- 
tein was detected in MHV-l-infected cells (Fig. l), this 
mRNA also appeared to be nonfunctional. 
Sequence analysis of HE gene 
We wanted to understand the molecular basis of the 
variable HE gene expression in different MHV strains 
and also the discrepancy between the expression of 
mRNA 2-1 and synthesis of HE protein by some vi- 
ruses. Therefore, the sequences of the HE gene region 
of different viruses were obtained by either direct RNA 
sequencing or DNA sequencing of PCR products. Oli- 
gonucleotides corresponding to the leader RNA and a 
conserved 3’-end region of the HE gene were used as 
primers for PCR. Due to the nested-set structure of the 
coronavirus mRNAs, these clones included sequences 
from the coding region of the HE gene, the leader-fu- 
sion site of mRNA 2-1, and its genomic intergenic se- 
quences. Thus, the 5’unique coding regions of both 
mRNA 2 and mRNA 2-l were obtained. Sequence data 
from the HE genes of these viruses revealed substan- 
tial numbers of base substitutions, deletions, and in- 
sertions spread throughout the coding region of gene 
2-l in most viruses. As a result, the open reading frame 
(ORF) for the HE protein was truncated in A59, MHV-1, 
MHV-2, and both isolates of MHV-3 (Fig. 3). Specifi- 
cally, in contrast to the HE genes of JHM and MHV-S, 
which had a coding capacity of 440 amino acids, that 
of A59 encoded only 14 amino acids, MHV-2, 97 
amino acids, MHV-3-Y, 27 amino acids, while that of 
MHV-3-L was 135 amino acids. Although MHV-1 did 
not synthesize mRNA 2-1, its ORF was capable of en- 
coding a protein of 268 amino acids. The usual initiat- 
ing AUG of the HE gene in several viruses was also 
mutated or deleted (Fig. 3) thus providing the potential 
for additional HE gene variation in different MHV 
strains. 
To confirm the sizes of the ORF predicted from the 
RNA sequence data, the HE genes of some of the vi- 
ruses were examined by in vitro translation. Capped 
RNAs were transcribed in vitro from cDNA clones us- 
ing T7 RNA polymerase, and then used for in vitro 
translation in either wheat germ extract or rabbit reticu- 
locyte lysate system. The sizes of the 35S-labeled 
translation products agreed with the predicted ORF 
(Fig. 4A): The MHV-3-L clone yielded a 14-kDa transla- 
tion product, whereas the MHV-3-Y clone yielded an 
4-kDa product. Furthermore, in the presence of canine 
pancreatic microsomal membrane, MHV-3-L RNA 
yielded two additional protein products (Fig. 4~3). The 
higher band possibly represented glycosylated prod- 
uct, since the ORF contained one potential N-linked 
glycosylation site. The middle band was of the same 
size as the primary translation product in the absence 
of membrane and thus represented the native product 
of 14 kDa. The lower band most likely represented the 
core protein, from which the signal peptide had been 
cleaved off. These results suggest that this truncated 
HE protein was properly translocated and processed in 
vitro. However, these protein products were not de- 
tected in infected cells (Fig. 1). 
The UCUAA copy number in the leader and 
intergenic sequence of the HE gene 
From studies with JHM(2) and JHM(3), it was con- 
cluded that the transcription of mRNA 2-l depends on 
the interaction between the repeated UCUAA se- 
quence motif in the leader RNA and the intergenic se- 
quences upstream of the HE gene (Makino and Lai, 
1989a; Shieh et a/., 1989). Similar conclusions were 
reached with JHM-DL(2) and JHM-DL(3). 
Sequence analysis of the intergenic regions of the 
HE gene and the leader RNA was further extended to 
all of the other viruses. Table 1 summarizes the inter- 
genie sequences preceding the HE gene. All viruses 
examined contained a stretch of UA-rich sequence sim- 
ilar to that of JHM. The only exception was A59, which 
had an A to G substitution, and correspondingly, did 
not synthesize mRNA 2-1, despite the fact that it con- 
tained two copies of UCUAA in the leader RNA (Makino 
and Lai, 1989a; Shieh et a/., 1989). The intergenic se- 
quence preceding the HE gene was slightly different 
from the consensus transcription initiation motif seen 
in most of the other MHV genes, i.e., gene 3 and gene 
7 (Table 1). This finding may explain why gene 2-1 was 
regulated by the number of UCUAA copies in the 
leader RNA, while the other genes were constitutively 
expressed. Since MHV-1 had an identical intergenic 
sequence preceding the HE gene (Table l), the failure 
of this virus to transcribe mRNA 2-l must have been 
due to the presence of three copies of UCUAA at the 
3’-end of leader sequence, or some other as yet unde- 
termined reason. 
The number of copies of UCUAA in the leader RNA of 
the various MHV strains was determined by primer ex- 
tension and direct RNA sequencing of genomic RNA. 
The results showed that MHV-S, MHV-2, MHV-3-L, 
and MHV-3-Y had two copies while MHV-1 had three 
(Fig. 5 and data not shown). As MHV-S, MHV-2 and 
both MHV-3 isolates transcribed mRNA 2-1, while 
MHV-1 did not (Fig. 2) these results further supported 
the correlation between the UCUAA copy number and 
expression of the HE gene. In each case, those viruses 
with three repeats did not transcribe mRNA 2-l effi- 
ciently. 
As described above, MHV-1 did not synthesize 
mRNA 2-1, but instead, made a novel mRNA smaller 
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..G................. A..T..T . . . . . . . . . . . . . . . . . . . ...*... c. .c . . . . . C..T . . . . . . . . . . . . ..C.G......G 
..G................ m.T..T . . . . . . . . . . . . . . . . . . . . . . . . ..C..C..C.....C..T..............C.G......G 
JHM 181 
A59 
HHV-S 
MN-1 
MHV-2 
MHV-3-L,Y 
ENNGHPKLDWLDLDPKLCNSGKISAKSGNS 
GAAAATAACGGTCATCCTATAGATTGGCTAGACCTTCCTC? 270 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . C . . . . . . . . G C A . ..*................... 1. . . ..*.......... 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T..T........G . . . . . . . . . . . . . . . ..A.GA..A.AC..A........C...... 
. . . . . . . . . ..G..C...........C.....T.....C.....G.....A . . . . . . . . . . . . . G . . ..G.... . . . . . . . . . ..T..C 
AGT.GCCTTTC... G.AG..T.ATA.G.ATA.G..TA..A.....G..........G..G..G.........T,~...GCG.....T..C 
. . . . . . . . . . . . . . . . . AGC..AT......T . . . . . ..ACC..A.G.G.....CC.......T.....C.....T..A........T..C 
JH!? 271 
A59 
MHV-S 
MHV-1 
MHV-2 
MHV-3-L,Y 
LFRSFHFTDFYNYTGEGDQIVFYEGVNFSP 
CTCTTCCGGAGTTTTCACTTCACTGATTTTTACAATTATAC--- uuvTGAGGGAGACCAAATTGTATTTTATGAAGGAGTTAATTTTAGTCCC 360 
. . . ..TA . . . . . . . . . . . . . . . . . . . . . . ..*.......................................................... 
. . . ..TA.......C..T..T.T . . . . . . . . . . . . . . ..T.A..A..A..C......G..A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
...... ..A..C..C..T ..T ..................................................................... 
... ..TA.A........T.....C.....C..........GT..C..A..TTC~..C A ...................... ..CC ..A 
..T..TAA.........T ..T ..... ..GG..T..C..C..A........T..T...G ..A ............................. 
JHM 361 
A59 
MHV-S 
mv-1 
MHV-2 
NHV-3-L,Y 
NHGFKCLAYGDNKRWMGNKAAFYARVYEKM 
RACCATGGCTTTAAATGCCTGGCTTATGGAGATAAAA 450 
.G .................... ..C ................................... CG ............................ 
.G .......................................................... CG ............................ 
.G..................T..C....CG..............................C G ........... ..c .......... T ... 
T.TGT...G.....G..TA..AA.A....G........T..G........T.........CG.......C..-A.T.....C ........ 
..T..C.CA....G-...T..T..G.G..T ..... ..C ............ T ....... ..CG...........m.....A ........ 
JSM 451 
A59 
%V-s 
XHV-1 
NHV-2 
MHV-3-L,Y 
AQYRSLSF~NVPYAYGGKAK~T~ICK~KTL 
GCCCAATATAGGAGCCTATCCTTTGTTAATGTGCCTTATGCC: ATGGGGGTAAAGCCAAGCCCACCTCCATTTGCAAACATAAAACTTTA 540 
.................. ..G ............ T ........... ..A.....T..A......G..............G.C..T ...... 
................................. T ............. A ... ..T..T.....T..T...........GG ........... 
........................... G ..... T .. ..C A .......... ..GT..T.....................G.C.C ....... 
..T..T...C.T........TA.AA.......TA....CA.A...AAT.....T..T.CT...GTTGCT..G..T..G..C.CT..A ..G 
~ 
..... T ...... ..T..T..T............T....CAGT.....T.....T..G..A..T........A..T..GG ........... 
JHM 541 
A59 
MHV-S 
MHV-1 
MHV-2 
MHV-3-L,Y 
TLNNPTFISKESNYVDYYYESEANFTLAGC 
ACACTCAACAACCCCACCTTCATCTCGAAGGAGTCCAATTATG~TGATTATTATTACGAGAGTGA~CT~TTTCACACTAGCAGGTTGT 630 
........ T .............. A ........... T ................. C T..........A .. ...................... 
....................... T ......................................................... CA ....... 
.T.....................A...........T....................T.........................T ....... 
..C..----.....T........TGGT......A.A.G.GCACC.A..........T.....C....A-A.C..T..GT.GCAT..A ..c 
............ ..T ........ T ......... ..T .... T ............... T ......................... A ....... 
JHM 631 
A59 
NHV-S 
MHV-1 
MHV-2 
MHV-3-L,Y 
DEFIVPLCVFNGHSKGSSSDPANKYYMDSQ 
GATGMTTTATAGTACCGCTCTGTGTTTTC~TG~CACTCC~GGGCAGTTCTTCGGACCCTGCC~C~ATATTATATGGACTCGCAG 720 
....................... ..G ... T ........ T ......... ..C........TG.......T..........CT.....T ... 
............... A ..... ..C....CT........T......A....C........T........T..........CT...G.T ... 
............................. T ..... ..G ..... G ............... T.A.........G.C ................ 
... ..G.....T..C---.....C..C..T........G.-------ATTTATCTAGTATG--------......GAT..TAGT ... 
..... G ........... A ......... ..T....i......G...T...........T........T..G............AGT ..A 
FIG. 3. Sequence of the HE gene starting from the upstream intergenic sites. JHM and A59 sequences have been published previously (Luytjes 
et a/., 1988; Shieh et al., 1989). Amino acid sequences are shown above the nucleotide sequence and represent that of JHM (Shieh era/., 1989). 
Open boxes indicate AUG initiation codons and black boxes indicate termination codons of ORFs. Dashed lines represent deletions. Insertions 
are shown underneath with brackets. The underlined sequence beginning at the position 797 of MHV-1 indicates the intergenic site for the novel 
mRNA. The double-underlined sequence at the 3’-end of the gene corresponds to the primer used for PCR. The sequences for MHV-1, -2, -3, 
and -4 have .been deposited with GenBank. Their accession numbers are M-6431 3, M-6431 4, M-6431 5. and M-6431 6, respectively. 
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SYYNMDTGVLYGLNCTLDVGNTAKDPGLDL 
JHN 721 AGTTACTATAATATGGATACTGGTGTCTTATATGGGTTGAACTGCACTTTGGATGTTGGCAATACCGCTAA~ATCC~GTCTTGATC?C 810 
A59 ................... T .................. C T.CG ..C .. ............ ..C..T ........................ 
MHV-S .................... C ... ..T ........... C..T.CG ..C ............... ..T.TAC.AA ................. 
MHV-1 GA....................................c..TGC....C.T...T................A...TTML- .......... 
MHV-2 TA...T........T.....A..GA.T...........T..T.C...C...A..A..------...A..---------..GT.G..CT .. 
MHV-3-L. Y .TG..........................T..C.....C..T.CG..CC.............C..T..AC.AA....A..C ...... ..T 
TCRYLALTPGNYKAVSLEYLLSLPSKAICL 
JHM 811 ACTTGTAGGTATCTTGCATTGACTCCTGGTAATTATAAGGCTGTGTCCTTAGAATATTTGTTAAGCTTACCCTCA~GGCTATTTGCCTC 900 
A59 ... ..c .................................................................................... 
MHV-S .................................................... .G..............................~ ..... 
MHV-1 .................. C5 ............................... G .......................... C ......... 
MI-IV-2 ..C....TC......T....AG...................CA.T.TRAAT....TA.......CTA.......T ............ ..G 
MHV-3-L,Y ..C....TT...TAC.T...A....................A..C..............A....CTA .................... ..G 
RKPKRFMPVQVVDSRWNSTRQSDNMTAVAC 
JHM 901 CGTAAGCCAAAGCGCTTTATGCCTGTGCAGGTAGTGGATTCAAGGTGGAATAGTACCCGCCAGTCTGACAATATGACCGCTGTAGCTTG~ 990 
A59 .A .. ..A ............................ T..C..........G...C.T ....... ..A .............. ..c ... C ... 
MHV-S .......... ..A .... C ............................................... A ......... ..T ............ 
MN-1 ...... T ................................................ G ..... T ............................ 
MHV-2 ...... ..T...GTG....C..C......A.....G.....T..A...C......ATA.G..A..............T...A.T..G ... 
MHV-3-L,Y ... ..A..C..AGTG........A...........T.....C..A.......A.G.TA.G..T..G..T........G.....T ...... 
QLPYCFFRNTSADYSGGTHDVHHGDFHFRQ 
JHM 991 CAGCTGCCATATTGCTTTTTCCGCAATACATCTGCGGATTATAGTGGTGGTAC~ATGATGTACACCATGGTGATTTTCATTTCAGGChG 1080 
A59 ............ ..T..C..T.....C.........A.............C..A.......CG ........................... 
MHV-5 .......................... C .......................... A .......................... C ......... 
MHV-1 ......................................... A ................................................ 
MN-2 C ....... ..T.A......T...G.CAG.AAT.....C.A...---C.TTT.....TCT........C...GC.GGA..T.CTAG C 
MHV-3-L,Y ::::C.........T..C.....A ..... T . ..A.c.G.....A .. ..A c . ............ ..T.........ACA..A..T..A ..A 
LLSGLLLNVSCIAQQGAFLYNNVSSSWPAY 
JHM 1081 TTATTGTCTGGTTTGTTACTTAATGTTTCCTGTATCGCCCA~AGGGTGCATTTCTTTATAATAACGTTAGCTCCTCTTGGCCAGCCTAT 1170 
A59 ................ ..TA...............T.............................T.....T .................. 
MHV-S ............. ..C..TA...............T.....A............G....C.....T ........................ 
MHV-1 ................ ..T .................. T . ..A ................. C ..... T ........................ 
MHV-2 A.C...............TA...............T.............................C......-............TT.T . 
MHV-3-L,Y ..G...........AC.TTAC.....GCAG.....TT..TT...C....................T........GCAG.....T.T.C; G 
GYGQCPTAANIGYHAPVCIYDPLPVVLLGV 
JHM 1171 GGGTATGGCCAGTGTCCAACGGCTGCTAACATTGGTTATAT~CACCTGTTTGTATTTATGACCCATTACCGGTCGTATTACTCGGTG~C 1260 
A59 ... ..C..T..T ......... ..A ................................ C ...... ..TC.C......A..C.G..A ... ..G 
MHV-S ... ..C..T..T...........A....................G...........C.....A..CCTT......A..C.G..A ... ..A 
MHV-1 ......... ..T ..................................................... G ......... A ....... A ...... 
MHV-2 .-C..C.....T...........A...........A....................G.....T..T.........A.......T ...... 
MHV-3-L,Y ..TTTT..G..C.....G...........T.....AGT...AA....C.....C..G..................A....G..G ... ..A 
LLGIAVLIIVFLILYFMTDSGVRLHEAZ 
JAM 1261 TTATTGGGTATAGCTGTGTTAATTATTGTTTTTCTTATTTTGTATTTCATGACGGATA~GGTGTTAGATTGCATGAGGCA~ 1344 
A59 .................. ..G ........ G . ..T.G.A.G.T ... ..T .................................... 
MHV-S .................. ..G ........ G . ..T.G..G..T.....T .................... 
MHV-1 .................................... ..G..T.....T .................... 
HHV-2 . ..c ....................... A ................. ..T .................... 
MHV-3-L,Y .................. ..G ........ G . ..T.GT.G..T ... ..T .................... 
FIG. 3-Continued 
than mRNA 2-1 and larger than mRNA 3 (Fig. 2). By 
performing PCR with a pair of oligonucleotides, one 
identical with the 5’-end of the leader RNA and the 
other complementary to the 3’-end region of the HE 
gene, the initiation site of this novel mRNA was deter- 
mined and compared with the corresponding genomic 
sequence (Fig. 6). As a result of mutations and a dele- 
tion in this region, the genomic sequence from nucleo- 
tides 794 to 804 (ATCCGGGTCTT) was converted to 
ATTTAA-TCTT, which resembled the consensus tran- 
scription initiation signal. Comparison of the genomic 
sequence with the sequence of the novel mRNA indi- 
cated that this was indeed the transcriptional initiation 
point for the mRNA species (Fig. 6). Thus, the specific 
expression of the novel mRNA in MHV-1 was most 
likely caused by the interaction of the three copies of 
UCUAA in the leader with the newly acquired inter- 
genie site in the middle of the HE gene. 
DISCUSSION 
The results presented in this paper show that the 
functional integrity of the HE gene is not well main- 
tained in murine coronaviruses. Of the MHV strains 
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FIG. 4. SDS-PAGE analysis of in vitro translation products of the 
HE gene of MHV-3-L (L2) and MHV-3-Y (Yac). A. RNAs transcribedin 
vitro from cDNA clones were translated in a wheat germ extract 
system in the presence of [35S]methionine (NEN Du pont). The arrow- 
heads indicate the translation products from MHV-3-L and two dif- 
ferent clones of MHV-3-Y. Lane M represents “C-labeled size 
markers (Gibco, BRL). “No RNA” lane was in vifro translation with no 
RNA. B. MHV-3-L RNA was translated in a rabbit reticulocyte lysate 
system with [35S]methionine. The two left lanes are molecular size 
markers. Membrane “+” lanes represent products translated in the 
presence of the canine pancreatic microsomal membrane. The 
membrane “-” lane was translated without membrane. Products 
were immunoprecipitated with either monoclonal anti-HE antibody 
(the third lane from left) or anti-JHM(2) polyclonal antibody (the forth 
and fifth lanes from left, which represented different in vitro transla- 
tion reactions). The specific precipitates are indicated by arrow- 
heads with a number; 1, glycosylated product; 2, native translation 
product: 3, core product from which the signal peptide had been 
cleaved off. The band which migrates around 30 kDa appears to be a 
nonspecific precipitate, since it was detected in only one out of three 
different immunoprecipitation reactions. 
examined, only two viruses (JHM and MHV-S) made an 
intact HE protein. Other viruses had a defective gene 
or were defective in transcription such that no HE pro- 
tein was synthesized. The failure to synthesize an HE 
protein was due to several different reasons in different 
MHV strains: (1) The mRNA for the HE protein (mRNA 
2-1) was not synthesized because the number of cop- 
ies of the UCUAA pentanucleotide in the leader se- 
quence was not optimum for transcription (e.g., JHM(3) 
and MHV-1, which contain three UCUAA copies), or 
the consensus intergenic sequence (e.g., A59) was 
mutated. (2) The mRNA was synthesized but due to 
sequence alterations resulting from mutations, dele- 
tions or insertions, the usual initiation codon of the HE 
ORF was lost, or the reading frame closed prematurely 
(e.g., A59, MHV-2, and MHV-3-Land MHV-3-Y). These 
findings are in striking contrast to the other three MHV 
structural protein genes, S, M, and N, which, despite 
some degree of sequence diversity, are consistently 
expressed and the ORFs are well-maintained. These 
results suggest that there is no selection pressure to 
preserve the complete HE ORF, and consequently, this 
gene has drifted into a pseudogene. Furthermore, 
TABLE 1 
PUTATIVE INTERGENIC SITE: LEADER FUSION SITE OF mRNA 2-1 
Leader (ucuAA)ucuAAucuAAAcuu 
HE gene JHM 5’.uaaUAAACUUauua 
A59 -uaaUAAGCUUauua 
MHV-S -uaaUAAACUUauua 
HMV-1 -uaaUAAACUUauua 
MHV-2 -uaaUAAACUUauua 
MHV-3-L -AaUAAAUCUAAuAa 
MHV-3-Y -AaUAAAUCUAAuAa 
Gene 3 (JHM) agcaUAAUCUAAACaug 
Gene 7 (JHM) AAucuAAucuAAAcuuu 
Novel mRNA Ml-IV-1 795 UUUAAUCUuga 
(JHM 795 uCCGGGucuuga) 
Note. The leader fusion sites of mRNA 2-1 of various MHV strains 
were obtained from PCR products of the 5’region of the mRNA, and 
are compared with the corresponding regions of genomic se- 
quences. Boldface capital letters represent common sequences be- 
tween leader RNA and the intergenic sequence of the genome, and 
thus are likely to be the leader fusion site. Divergent nucleotides are 
shown in regular capital letters. Other nucleotides are shown in 
lower case. As a comparison, the gene 3 and gene 7 intergenic site 
and the novel mRNA initiaion site within the HE gene of MHV-1 are 
shown. The sequence in parenthesis represents the corresponding 
JHM sequence in the HE gene. 
since some of the MHV strains examined in this study 
did not express HE, this protein is not essential for viral 
replication. This conclusion is consistent with the hy- 
pothesis that this gene might have been derived from 
influenza C virus by a fortuitous RNA-RNA recombina- 
tion event (Luytjes et al., 1988). Nevertheless, the JHM 
and MHV-S viruses have maintained this gene despite 
extensive passages in tissue culture and animals. 
MHV-I 
AGCT AGCT _. 
5’ 
/E 
II L A 
T 
II ,I 
FIG. 5. RNA sequencing of the 3’-end region of the leader RNA of 
MHV-1 and MHV-S. Top, 5’-end; bottom, 3’.end. The brackets indi- 
cate the UCUAA pentanucleotide. 
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genome mRNA 
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FIG. 6. DNA sequencing of the junction region between the leader 
and the body of the novel mRNA of MHV-1. The sequences are 
extended from the bottom to the top, in the 5’ to 3’ direction. The 
sidelined genomic sequence (left side) corresponds to the sidelined 
UCUAA sequence in the leader (right side). The sequence indicated 
in the middle shows the sequence which is homologous between 
the mRNA and the genome in the HE gene. 
Also, the JHM virus with an expressed HE protein was 
naturally selected during JHM passages in tissue cul- 
ture (Makino and Lai, 1989a). Thus, the presence of HE 
protein may have provided selective advantages under 
certain conditions. Interestingly, cold-sensitive mu- 
tants isolated from a persistent MHV-S infection of Kir- 
sten murine sarcoma virus-transformed BALB/C cells 
failed to make HE protein (Yoshikura and Tejima, 
1981). Also, Morris eta/. (1989) have isolated JHM vari- 
ants from Wistar Furth rats with a JHM-induced demye- 
linating disease. Besides a change in the S protein, 
these variants had a large deletion in the HE gene, 
resulting in the loss of HE protein expression (La Mon- 
ica et al., 199 1). These data further suggest that under 
certain conditions, the HE protein may provide some 
selection advantage. 
The HE protein also is present in some other corona- 
viruses which have a hemagglutinin activity including 
BCV and human coronavirus OC43, (Vlasak et a/., 
1988b). The HE protein of BCV also exhibits an acetyl- 
esterase activity similar to the receptor destroying ac- 
tivity of influenza C virus (Vlasak et a/., 198813). A similar 
activity has been demonstrated for the HE protein of 
MHV (Yokomori et al,, 1989). Data have been obtained 
which suggest that the HE protein is required for BCV 
infectivity. HE protein was the target of neutralizing 
monoclonal antibodies, which also inhibited hemagglu- 
tinin and esterase activities (Deregt and Babiuk, 1987; 
Parker eta/., 1990). In addition, treatment with diisopro- 
pyl fluorophosphate (DFP), an inhibitor of esterase, 
was found to inhibit virus replication (Vlasak et al., 
1988a). Similar requirements have not been demon- 
strated for MHV. It should be noted, however, that the 
presence of the HE protein does alter some biological 
properties of the virus. For example, in cultured cells, 
JHM(2) became dominant over JHM(3) after serial undi- 
luted passages (Makino and Lai, 1989a). In mice, 
JHM(2) showed greater virulence and neurotropism 
than JHM(3) (Yokomori, unpublished data). Finally, pas- 
sive immunization with monoclonal antibodies against 
HE protein protected mice from JHM(2) infection (Yoko- 
mori, unpublished data). These data suggested that 
HE may play a role in neuronal infection. 
Although MHV-3 isolates examined retained a trun- 
cated HE ORF, and a protein product could be synthe- 
sized and properly processed in an in vitro translation 
system, no HE-related proteins could be detected in 
infected cells. The failure to detect these truncated HE 
proteins in viva was not readily apparent. Perhaps the 
predicted initiating AUG was not in an ideal context in 
infected cells, although the sequence around this AUG 
agrees with the optimum translation context described 
by Kozak (1987). Also, the truncated protein products 
may degrade rapidly; however, even short pulse-label- 
ing (15 min) did not reveal any products (Fig. 1). Addi- 
tionally, because the truncated ORFs retained the pu- 
tative esterase domain and signal sequence but lacked 
the C-terminal membrane-anchoring domain, we have 
investigated the possibility that the truncated HE pro- 
tein may have been released into the media. No HE- 
specific esterase activity was detected in supernatants 
from infected cells (data not shown). Thus, the reason 
that no truncated HE protein was detected in these 
MHV strains remains unclear. 
Another interesting characteristic of the HE gene is 
its transcriptional control by the copy number of 
UCUAA pentanucleotide sequence in the leader RNA. 
Both this report and previous publications (Makino and 
Lai, 1989a; Yokomori et al., 1989) indicate that only 
JHM variants with two copies of UCUAA in the leader 
expresses mRNA 2-1 efficiently, whereas JHM variants 
with three copies of UCUAA transcribe only small 
amounts of this mRNA (Makino and Lai, 1989; Shieh et 
al., 1989). This mechanism of transcriptional control 
also was confirmed with a variant of JHM, JHM-DL. 
Furthermore, we found that other MHV strains also uti- 
lized the same transcriptional regulation. Strains MHV- 
S, MHV-2, and MHV-3 had two UCUAA copies and 
expressed a large amount of mRNA 2-1, whereas 
MHV-1 possessed three copies and did not express 
mRNA 2-1, even though it had the same intergenic 
sequence preceding the gene as other MHVs. In addi- 
tion, MHV-1 synthesized a smaller mRNA from a novel 
downstream site which had a sequence similar to the 
656 YOKOMORI. BANNER. AND IAI 
consensus transcriptional initiation signal (UUlJ/MJ- 
CUU vs UCUAAUCUA, respectively). These results 
strongly suggest that MHV RNA transcription results 
from an interaction between the leader RNA and the 
intergenic sequence preceding each gene, although 
the precise mechanism for this transcriptional control 
is not yet clear. The differential control of HE gene tran- 
scription by the leader RNA may further our under- 
stariding of the mechanism of MHV transcription. 
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